KCT0003600
Completed
未知
Effects of Dapagliflozin Compared with Glimepiride on Body Composition in Patients with Type 2 Diabetes Inadequately Controlled with Metformin
AstraZeneca Korea0 sites160 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Endocrine, nutritional and metabolic disease
- Sponsor
- AstraZeneca Korea
- Enrollment
- 160
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1 . Adults with T2DM(Type 2 diabetes mellitus) (Male or female, \=19 and \=75 years).
- •2 . Patients with insufficient glycaemic control (HbA1c \=7\.0% and \<10\.0% in recent 4 weeks).
- •3 . Patients with an unchanged dose of metformin (\=1,000 mg/day) for \=8 weeks prior to randomisation.
- •4 . Written informed consent.
- •5 . WOCBP(Women of child bearing potential) were to take precautions to avoid pregnancy throughout the study and for 4 weeks after intake of the last dose.
- •\- WOCBP(Women of child bearing potential) had to have a negative urine pregnancy test at screening visit. Women of child bearing potential included any female who had experienced menarche and who had not undergone successful surgical sterilisation (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or was not postmenopausal.
- •\- WOCBP(Women of child bearing potential) had to be willing to use a medically accepted method of contraception that was considered reliable in the judgment of the Investigator.
Exclusion Criteria
- •1 . Type 1 diabetes or history of diabetic ketoacidosis.
- •2 . Pregnant or breast\-feeding patients.
- •3 . eGFR \<60 mL/min/1\.73 m2 (MDRD, Modification of Diet in Renal Disease) at Visit 1\.
- •4 . Indication of active liver disease (AST(Aspartate aminotransferase)/ALT(Alanine aminotransferase)/total bilirubin \>3 × upper limits of normal) at Visit 1\.
- •5 . Acute coronary syndrome, stroke, or transient ischaemic attack within 3 months prior to randomisation
- •6 . Bariatric surgery within 2 years; treatment of anti\-obesity drugs 3 months prior to randomisation; any treatment leading to unstable body weight. (Unstable body weight was considered reliable in the judgement of the Investigator.)
- •7\. Any kind of surgery using foreign metallic materials.
- •8\. History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time.
- •9\. History of any other malignancy within 5 years (with the exception of successfully treated non\-melanoma skin cancers)
- •10\. History of alcohol or drug abuse judged by physician within 3 months prior to randomisation.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT04240171Damanhour University60
Recruiting
Phase 3
Effects of Dapagliflozin and Empagliflozin in Myocardial DysfunctioIRCT20111206008307N45Tabriz University of Medical Sciences75
Completed
Not Applicable
Comparison of Dapagliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized,Open-Label, Active-Controlled Trialtype 2 diabetes mellitus, NAFLD, NASHJPRN-UMIN000030548Saitama Medical University Hospital100
Not yet recruiting
Phase 4
Comparison of Dapagliflozin and Pioglitazone for Non-Alcoholic Fatty Liver Disease in Type 2 DiabetesHealth Condition 1: K760- Fatty (change of) liver, not elsewhere classifiedHealth Condition 2: E116- Type 2 diabetes mellitus with other specified complicationsCTRI/2024/07/071087Babra
Not yet recruiting
Not Applicable
Dapagliflozin in Heart FailureCTRI/2022/11/047725Sanjay Kumar R